| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
ARVN
Arvinas Holding Company
|
Oct 08, 2026 | HOLD |
Strong Buy
+267.5% avg upside
28 analysts
|
$12.00
56.98% Upside
|
· | · |
|
CGEM
Cullinan Management
|
Oct 07, 2026 | BUY |
Strong Buy
+126.7% avg upside
16 analysts
|
$42.00
170.40% Upside
|
· | · |
|
GLUE
Monte Rosa Therapeutics
|
Oct 02, 2026 | BUY |
Strong Buy
+117.6% avg upside
16 analysts
|
$27.00
162.18% Upside
|
-1.7% | · |
|
FHTX
Foghorn Therapeutics
|
Oct 02, 2026 | HOLD |
Buy
+415.3% avg upside
17 analysts
|
$2.00
0.00% Upside
|
-1.0% | · |
|
RCUS
Arcus Biosciences
|
Sep 30, 2026 | BUY |
Strong Buy
+46.6% avg upside
21 analysts
|
$43.00
76.13% Upside
|
-4.8% | · |
|
ACET
Adicet Bio
|
Sep 29, 2026 | BUY |
Strong Buy
+363.8% avg upside
14 analysts
|
$28.00
399.06% Upside
|
-9.5% | · |
|
CMPX
Compass Therapeutics
|
Sep 23, 2026 | HOLD |
Strong Buy
+647.7% avg upside
20 analysts
|
$1.00
0.66% Upside
|
-14.7% | · |
|
CRBP
Corbus Pharmaceuticals
|
Sep 15, 2026 | BUY |
Strong Buy
+550.5% avg upside
20 analysts
|
$30.00
457.57% Upside
|
-11.4% | · |
|
CBIO
Crescent Biopharma
|
Sep 14, 2026 | BUY |
Strong Buy
+58.2% avg upside
17 analysts
|
$27.00
81.13% Upside
|
-27.2% | · |
|
TYRA
Tyra Bioscience
|
Sep 11, 2026 | BUY |
Strong Buy
+117.9% avg upside
17 analysts
|
$53.00
165.86% Upside
|
-9.5% | · |
|
RVMD
Revolution Medicines
|
Aug 27, 2026 | BUY |
Strong Buy
+8.5% avg upside
35 analysts
|
$225.00
18.52% Upside
|
-13.6% | · |
|
IDYA
IDEAYA Biosciences
|
Aug 20, 2026 | BUY |
Strong Buy
+33.4% avg upside
29 analysts
|
$60.00
66.12% Upside
|
-4.5% | · |
|
REPL
Replimune Group
|
Aug 17, 2026 | BUY |
Buy
+74.1% avg upside
14 analysts
|
$19.00
41.66% Upside
|
-8.3% | · |
|
PYXS
Pyxis Oncology
|
Aug 14, 2026 | BUY |
Strong Buy
+303.6% avg upside
15 analysts
|
$6.00
195.51% Upside
|
-32.6% | · |
|
TNGX
Tango Therapeutics
|
Aug 12, 2026 | BUY |
Strong Buy
+65.3% avg upside
15 analysts
|
$39.00
63.73% Upside
|
-14.7% | · |
|
BDTX
Black Diamond Therapeutics
|
Aug 06, 2026 | BUY |
Strong Buy
+683.1% avg upside
12 analysts
|
$14.00
664.97% Upside
|
-6.2% | · |
|
KURA
Kura Oncology
|
Jul 28, 2026 | BUY |
Strong Buy
+147.9% avg upside
27 analysts
|
$36.00
239.64% Upside
|
+13.1% | · |
|
CTMX
CytomX Therapeutics
|
Jun 04, 2026 | BUY |
Strong Buy
+324.9% avg upside
21 analysts
|
$11.00
328.06% Upside
|
-19.5% | · |
|
CGON
CG Oncology, Inc.
|
May 18, 2026 | BUY |
Strong Buy
+34.2% avg upside
17 analysts
|
$80.00
25.26% Upside
|
+0.5% | · |
|
APRE
Aprea Therapeutics
|
May 14, 2026 | BUY |
Buy
+3688.4% avg upside
7 analysts
|
$6.00
892.74% Upside
|
-32.4% | · |
|
AVTX
Avalo Therapeutics
|
May 14, 2026 | BUY |
Strong Buy
+286.7% avg upside
20 analysts
|
$34.00
148.99% Upside
|
-21.1% | · |
|
EIKN
Eikon Therapeutics, Inc.
|
May 12, 2026 | SELL |
Strong Buy
+231.8% avg upside
5 analysts
|
$5.00
32.97% Downside
|
+35.2% | · |
|
JANX
Janux Therapeutics Inc
|
May 08, 2026 | BUY |
Strong Buy
+144.3% avg upside
22 analysts
|
$36.00
95.76% Upside
|
+29.7% | · |
|
HOWL
Werewolf Therapeutics
|
Dec 19, 2025 | HOLD |
Strong Buy
+609.0% avg upside
8 analysts
|
$1.00
2.16% Upside
|
+32.5% | · |
|
ZNTL
Zentalis Pharmaceuticals
|
Aug 07, 2025 | HOLD |
Strong Buy
+412.3% avg upside
20 analysts
|
$4.00
51.45% Upside
|
+191.0% | · |
|
GYRE
Gyre Therapeutics
|
Jul 14, 2025 | BUY |
Strong Buy
+197.9% avg upside
15 analysts
|
$27.00
283.52% Upside
|
-16.7% | · |
|
GERN
Geron
|
May 08, 2025 | BUY |
Strong Buy
+249.7% avg upside
19 analysts
|
$6.00
389.76% Upside
|
+10.3% | · |
|
GILD
Gilead Sciences
|
Nov 19, 2021 | BUY |
Strong Buy
-20.2% avg upside
66 analysts
|
$67.00
55.63% Downside
|
+27.5% | · |
|
ABUS
Arbutus Biopharma
|
Mar 08, 2021 | BUY |
Strong Buy
+110.2% avg upside
15 analysts
|
$6.00
42.21% Upside
|
-11.1% | · |
|
CRVS
Corvus Pharmaceuticals
|
Oct 05, 2020 | BUY |
Strong Buy
+144.9% avg upside
14 analysts
|
$8.00
23.92% Downside
|
-2.9% | · |
|
NBRVF
Nabriva Therapeutics
|
Mar 19, 2020 | HOLD |
Buy
+13374900.0% avg upside
9 analysts
|
$10.00
9999899.97% Upside
|
· | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.